An observational study in Cerebral Arteriovenous Malformation, sponsored by yuanli Zhao. Status unknown at 1 site in China. Open to participants aged 1 Year to 80 Years. Per ClinicalTrials.gov, last updated 2020-10-20.
Sponsored by yuanli Zhao · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Intracranial Arteriovenous Malformations with a site in China — 4 open to participants now, 4 under way, none of them phase 3. Intracranial Arteriovenous Malformations · China.
Among the 13 studies in Intracranial Arteriovenous Malformations with a site in China, this one is one of 2 that started in 2012, is one of 7 observational ones, and was the 7th registered.
43 studies on the registry are indexed under Intracranial Arteriovenous Malformations; 15 are open to participants now.
Browse Intracranial Arteriovenous Malformations studies →4 of the 13 studies in Intracranial Arteriovenous Malformations with a site in China are open now. Recruiting first, the newest first:
Duan Chuanzhi · Sites in China
Beijing Tiantan Hospital · Sites in China
Ages 18–70
Zhuhai Tonbridge Medical Tech. Co., Ltd. · Sites in China
Ages 18–80
Beijing Tiantan Hospital · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 13 Intracranial Arteriovenous Malformations studies recruiting now, 10 (77%) set no upper age limit and 2 (15%) stop at 75 or younger; 6 take children under 18; 1 takes healthy volunteers.
This study: 1 Year to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 2 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 140 across 25 observational studies indexed under Intracranial Arteriovenous Malformations.
Median enrollment 460 across the 6 interventional studies, 300 across the 7 observational. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 13 have an industry lead sponsor. The 8 most frequent:
yuanli Zhao is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
yuanli Zhao has 1 study filed under Intracranial Arteriovenous Malformations — fewer than ten, so there is no comparison to draw.
1 of the studies in Intracranial Arteriovenous Malformations with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07118631Beijing Tiantan HospitalClinical Study on Emergency Treatment of Cerebral Arteriovenous Malformation Bleeding | 2027-11-30 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies in Intracranial Arteriovenous Malformations with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Cerebral Arteriovenous malformations (AVMs) are abnormal tangles which are usually believed congenital. AVM can cause different symptoms depending on where it is located, but the most common symptoms are intracranial hemorrhage and seizure. Outcomes of AVM patients can be very different due to factors like the location of lesion, age, sex etc. Generally, more early the intervention was taken, the risk of adverse events would be lower. But the selection of surgical timing for pediatric AVM patients is hard to judge, due to children's cerebral vessels angioarchitecture can be still developing with their age. Some previous studies indicated that there is no difference in intervention outcomes between pediatric and adult AVM patients, so pediatric patients should undergo more aggressive intervention. DOPA study aims to compare the clinical intervention outcomes of both pediatric and adult patients with eloquent region cerebral arteriovenous malformations, helping to determine the treatment strategy.
Follow-up: In the investigators' neurosurgical center, follow-up was conducted for all participants at the first 3-6 months and annually after discharge by clinical visit and telephone interview.
Study overview: DOPA will aim on outcomes of both pediatric and adult AVMs patients who underwent intervention in investigators' institution. Intervention strategies contains microsurgical resection, embolization, embolization + radiosurgery, and single-stage hybrid surgery (embolization + resection). Outcomes will be measured by a neurologist using Modified Rankin Scale (mRs). Participants' mRs\<2 will be considered as a good outcome and investigators will keep follow-up with every patient for at least 3 years.
Sample size: About 300 patients will be enrolled in this study, and adults and children will account for half. All kinds of intervention will be included. The distribution of different strategies is excepted as: 30% resection, 20% embolization, 30% embolization + radiosurgery and 20% hybrid surgery.
Study endpoints: The patients' mRs, occlusion rate and complication will be evaluated at 2 weeks, discharge from hospital, 1 year and 3 years after the first-time intervention.
Patients with brain arteriovenous malformation which located in eloquent area.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
1. AVM patients' age under 18-years-old who underwent intervention in investigators' institution. 2. Patients' lesions were located in eloquent and confirmed by image.
1. AVM patients' age over 18-years-old who underwent intervention in investigators' institution. 2. Patients' lesions were located in eloquent and confirmed by image.
modified Ranking Scale score at 2 weeks after the operation
The scale runs from 0-6, running from perfect health without symptoms to death. 0 - No symptoms. No significant disability. Able to carry out all usual activities, despite some symptoms. Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities. Moderate disability. Requires some help, but able to walk unassisted. Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted. Severe disability. Requires constant nursing care and attention, bedridden, incontinent. Dead
Time frame: 2 weeks
modified Ranking Scale score when discharge
The scale runs from 0-6, running from perfect health without symptoms to death. 0 - No symptoms. No significant disability. Able to carry out all usual activities, despite some symptoms. Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities. Moderate disability. Requires some help, but able to walk unassisted. Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted. Severe disability. Requires constant nursing care and attention, bedridden, incontinent. Dead
Time frame: Discharge (assessed up to 10 days)
modified Ranking Scale score at 1 years after the operation
The scale runs from 0-6, running from perfect health without symptoms to death. 0 - No symptoms. No significant disability. Able to carry out all usual activities, despite some symptoms. Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities. Moderate disability. Requires some help, but able to walk unassisted. Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted. Severe disability. Requires constant nursing care and attention, bedridden, incontinent. Dead
Time frame: 1 years
modified Ranking Scale score at 3 years after the operation
The scale runs from 0-6, running from perfect health without symptoms to death. 0 - No symptoms. No significant disability. Able to carry out all usual activities, despite some symptoms. Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities. Moderate disability. Requires some help, but able to walk unassisted. Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted. Severe disability. Requires constant nursing care and attention, bedridden, incontinent. Dead
Time frame: 3 years
Obliteration rate
Confirmed by postoperative DSA or MRI/magnetic resonance angiography
Time frame: At least 1 year, up to 3 years
Started Apr 2012 (actual). Primary completion is estimated for Nov 2024, 151 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Intracranial Arteriovenous Malformations →
yuanli Zhao